UNSPSC 51352404: Drospirenone/estradiol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352404 Drospirenone/estradiol, a Commodity code, encompasses oral contraceptive pharmaceuticals that state and local governments procure through pharmacy benefit programs, cooperative purchasing alliances, and direct-to-manufacturer initiatives aimed at managing prescription costs and improving access across employee health plans and Medicaid populations. State and local purchasing bodies—primarily state health and human services departments and multistate cooperative purchasing alliances—are actively soliciting drospirenone/estradiol products as part of broader generic pharmaceutical procurement frameworks. The procurement models reflect a shift toward direct contracting with manufacturers and managed sourcing through authorized wholesalers to reduce intermediary margins and negotiate net pricing without traditional rebate structures.

Recent activity concentrates in Texas and Minnesota. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs, seeking vendor capabilities to establish contracts outside of pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, closing March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. MMCAP requires vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), maintain cGMP and DSCSA compliance, hold minimum $5 million commercial general liability insurance, and accept a 3 percent administrative fee; evaluation emphasizes price competitiveness at 75 percent weight. Both solicitations signal state and local interest in consolidating pharmaceutical procurement, standardizing product specifications by National Drug Code, and leveraging cooperative mechanisms to negotiate lower net pricing for generic contraceptive products.